Ichthyosis Prematurity Syndrome (IPS) Cell Models for Research

Ichthyosis Prematurity Syndrome (IPS) is a rare autosomal recessive disorder characterized by premature birth, thick caseous desquamating epidermis, respiratory distress, and subsequent ichthyosis. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 1,000,000 individuals worldwide. The condition is caused by mutations in the SLC27A4 gene, which encodes fatty acid transport protein 4 (FATP4). Clinically, IPS presents with respiratory distress due to abnormal lung development, and skin barrier dysfunction leads to dehydration and infection risk. Long-term outcomes are generally favorable with supportive care, but the disease significantly impacts quality of life. Research on IPS is crucial for understanding skin barrier function, lipid metabolism, and neonatal respiratory physiology.

IPS serves as an excellent model for studying lipid metabolism and skin barrier formation. The disease is monogenic, making it amenable to gene editing. Public datasets such as those from NCBI Gene and ClinVar provide mutation information. Open questions include the precise role of FATP4 in keratinocyte differentiation and the mechanisms linking SLC27A4 mutations to premature birth. Gene-edited cell models allow researchers to dissect these pathways in a controlled environment.

The primary pathway affected in IPS is fatty acid transport and metabolism. FATP4 is a long-chain fatty acid transporter localized to the endoplasmic reticulum and plasma membrane. Its dysfunction leads to impaired uptake of fatty acids into keratinocytes, resulting in abnormal lipid composition in the stratum corneum. This disrupts the skin barrier, leading to transepidermal water loss and ichthyosis. Additionally, FATP4 is involved in the synthesis of acyl-CoA, which is essential for lipid modification of proteins and ceramide production. The pathway can be described as:

1. Fatty acid uptake: FATP4 facilitates transport of long-chain fatty acids across the plasma membrane.

2. Activation: Fatty acids are converted to acyl-CoA by FATP4's acyl-CoA synthetase activity.

3. Lipid synthesis: Acyl-CoA is used for synthesis of ceramides, phospholipids, and triglycerides.

4. Barrier formation: These lipids are secreted into the extracellular space to form the lipid envelope of the stratum corneum.

Mutations in SLC27A4 lead to reduced or absent FATP4 activity, causing a deficiency in lipid synthesis and impaired barrier formation.

Data compiled from ClinVar and literature.

Although IPS is primarily a lipid metabolism disorder, downstream signaling pathways are affected:

• • PPAR signaling: FATP4 is a target of PPARγ and PPARα. Reduced FATP4 leads to altered PPAR signaling, affecting keratinocyte differentiation.
• • Ceramide metabolism: Impaired fatty acid transport reduces ceramide synthesis, which is crucial for skin barrier integrity.
• • Inflammatory pathways: Skin barrier disruption triggers inflammation, activating NF-κB and cytokine production (e.g., IL-1, TNF-α).
• • Epidermal differentiation: Abnormal lipid composition affects keratinocyte differentiation markers such as involucrin and loricrin.

Organoids recapitulate skin architecture and are useful for studying barrier function. Gene-edited organoids with SLC27A4 knockouts are valuable for drug testing.

• • Slc27a4 knockout mouse: Global knockout is embryonic lethal, but conditional knockout in skin leads to ichthyosis-like phenotype.
• • Fatp4 mutant mouse (spontaneous): The 'wrinkly skin' (wrt) mouse has a mutation in Slc27a4 and exhibits ichthyosis.
• • Patient-derived xenograft (PDX): Not commonly used for IPS due to rarity, but skin grafts from patients can be transplanted onto immunodeficient mice.
• • Induced models: CRISPR-generated knock-in mice with specific SLC27A4 mutations are being developed.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise SLC27A4 mutations. These models allow researchers to study the effects of specific mutations in a controlled genetic background. For example:

• • SLC27A4 knockout cell lines: Complete loss of FATP4, mimicking null mutations.
• • Knock-in point mutations: Introduction of patient-specific mutations (e.g., p.Cys168Tyr) to study their impact on protein function.
• • Reporter lines: Tagging FATP4 with GFP to track localization and expression.

These gene-edited models are commercially available from several sources, providing sequence-verified, quality-controlled cells that accelerate research. They are essential for functional studies, drug screening, and understanding genotype-phenotype correlations.

Gene-edited cell lines are used to validate the function of SLC27A4 and its variants. For example, CRISPR knockout of SLC27A4 in keratinocytes leads to reduced fatty acid uptake and altered lipid profiles, confirming its role. Knock-in of patient mutations can reveal whether specific mutations affect protein stability, localization, or enzymatic activity. These models also enable genome-wide screens to identify modifiers of FATP4 function.

Isogenic pairs (wild-type vs. SLC27A4 knockout) are used to screen for compounds that restore lipid synthesis or improve barrier function. High-throughput screening can identify drugs that upregulate alternative fatty acid transporters or enhance PPAR signaling. Additionally, resistance mechanisms to drugs that target lipid metabolism can be studied using these models.

CRISPR-based synthetic lethality screens can identify genes that are essential in SLC27A4-deficient cells but not in wild-type cells. These genes may serve as therapeutic targets. Additionally, transcriptomic and proteomic analyses of gene-edited cells can reveal biomarkers of disease activity, such as altered cytokine secretion or lipid species.